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OBJECTIVE: This study proposes a new approach that considers uncertainty in predicting and quantifying the
presence and severity of diabetic peripheral neuropathy.
METHODS: A rule-based fuzzy expert system was designed by four experts in diabetic neuropathy. The model
variables were used to classify neuropathy in diabetic patients, defining it as mild, moderate, or severe. System
performance was evaluated by means of the Kappa agreement measure, comparing the results of the model with
those generated by the experts in an assessment of 50 patients. Accuracy was evaluated by an ROC curve analysis
obtained based on 50 other cases; the results of those clinical assessments were considered to be the gold standard.
RESULTS: According to the Kappa analysis, the model was in moderate agreement with expert opinions. The ROC
analysis (evaluation of accuracy) determined an area under the curve equal to 0.91, demonstrating very good
consistency in classifying patients with diabetic neuropathy.
CONCLUSION: The model efficiently classified diabetic patients with different degrees of neuropathy severity. In
addition, the model provides a way to quantify diabetic neuropathy severity and allows a more accurate patient
condition assessment.
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INTRODUCTION
Diabetic sensorimotor polyneuropathy (DSPN) is the most
common chronic complication associated with diabetes
mellitus. DSPN encompasses a group of clinical and
subclinical syndromes with varied etiologies and clinical
and laboratorial manifestations, defined by the progressive
diffuse or focal degeneration of peripheral somatic and
autonomic nerve fibers (1). Its prevalence is directly related
to diabetes duration, patient age, and metabolic control.
Approximately20%ofdiabeticpatientswilldevelopclinically
significant neuropathy within 10 years of diabetes onset, and
this proportion can increase to 50% after 10 or 15 years (2).
Somatosensory inputs decrease as diabetic neuropathy
advances, and motor output becomes progressively more
impaired. These issues may lead to the higher instability and
kinematic abnormalities observed during locomotion and
static posture in diabetic neuropathic patients (3-5). Sensory,
motor, and autonomic deficits may increase the risk of falling
and ulcer formation in these patients (6,7).
The diagnosis of DSPN is generally made based on
neurologic signs and symptoms and electrophysiologic
measurements (8). However, health experts define the
degree of neuropathy in a subjective way. Because neuro-
pathy onset is insidious and manifests differently for each
patient, expert experience plays an important role in the
classification of neuropathy.
Many screening instruments with numerous composite
scores are used to evaluate neuropathy. The tools that are
most frequently used in the literature are the Michigan
Neuropathy Screening Instrument questionnaire (MNSIq)
and Physical Assessment (9) and the Diabetic Neuropathy
Symptom (DNS) score, both of which are used solely for
screening (10). Neither instrument provides a disease
severity rating. Other instruments, such as the Neuropathy
Disability Score (NDS) (11), Neuropathy Impairment Score
(NIS) (12), Toronto Clinical Scoring System (TCSS) (13), and
Clinical Neuropathy Examination (CNE) (14,15), assign
patients to different disease levels.
Although these questionnaires are widely used in clinical
practice, there is no consensus regarding which tool is best
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151suited for disease diagnosis or severity evaluation. Thus, it
is common for individual clinics to develop their own
protocols, in which specialized laboratory tests are used in
conjunction with questionnaires (16).
The gold standard for detecting DSPN is the nerve
conduction velocity test. It can diagnose sensory and motor
losses due to neuropathy even when dysfunction is
subclinical, and it can predict ulceration and mortality in
diabetic patients (8,17,18). However, this invasive, painful
test must be performed by specialists, and it is not
commonly available in public health units.
The 10-g monofilament evaluation is another specialized
test that is strongly recommended by the International
Consensus on the Diabetic Foot. Monofilament evaluation is
a good tool to assess the loss of protective sensation related to
diabetic neuropathy (19). It has a high reproducibility and
specificity and may be used to predict ulceration and
amputation risks (20).
Glycemic control may be considered as an auxiliary
measure for predicting chronic diabetes mellitus complica-
tions, including DSPN. However, this information is
questionable because daily glycemic rates are highly
variable. The clinical measurement of glycosylated hemo-
globin (HbA1c) is more recommended for diabetes manage-
ment. Maintaining HbA1c levels below 6.5% is a major goal
of diabetes management because A1c levels correlate well
with diabetes complications risks (21).
The tests considered here involve some uncertainties
with respect to the measurement process and subsequent
diagnosis. Furthermore, the boundary between sickness
and health is not always clear. When this boundary is
defined, the classification of severity follows binary logic,
ignoring the fact that complications can represent contin-
uous processes. Furthermore, severity classification
depends on a subjective analysis by the examiner. It is
important to consider these uncertainties to obtain a
precise classification of DSPN severity. One of the most
powerful tools to deal with this type of data is fuzzy set
theory.
Fuzzy set theory was introduced by Lotfi Zadeh in 1965. It
is a mathematical entity that was developed to handle
problems in which there is uncertainty about whether an
element is part of a certain set. Fuzzy sets structure makes it
possible to deal with the concept of partial truths and the
elaboration of linguistic variables (22). Thus, this theory
allows us to assess the degree of diabetic neuropathy.
In this paper, we propose a fuzzy expert-based rule
system for quantifying diabetic neuropathy to categorize
patients into severity subsets.
METHODS
Data acquisition
The dataset was composed of 50 real cases from the
Hospital of the University of Sa ˜o Paulo (Ethics Committee
protocol 0305/08).
The inclusion criteria were: diagnosis of type II diabetes;
less than 65 years old; no lower limb amputation or severe
orthopedic foot deformities (e.g., Charcot arthropathy)
confirmed by radiography; no peripheral or central vesti-
bulopathy or any other neurological disease unrelated to
diabetes. These criteria were verified by a staff physician
from the University Hospital.
Model development
Fuzzy rule-based models have a simple structure and
consist of four major components: 1) a fuzzification module,
which translates crisp inputs (classical measurements) into
fuzzy values through linguistic variables; 2) an if-then fuzzy
rule base, which consists of a set of conditioned fuzzy
propositions; 3) an inference method, which applies fuzzy
reasoning mechanisms to obtain outputs (i.e., carries out the
computation using fuzzy rules); and 4) a defuzzification
module, which translates fuzzy outputs back to crisp values,
if necessary (22).
The fuzzy model was elaborated based on the experience
and knowledge of four diabetic neuropathy experts. These
experts considered the following inputs as the most im-
portant variables: symptom assessment based on the MNSI
questionnaire score, sign examination based on the MNSI
Physical Assessment score, level of HbA1c, and the duration of
diabetes, measured in years. The chosen tests require only
simple procedures and can thus be applied in a clinical
environment without the use of sophisticated equipment or
specialized personnel.
The experts defined limiting values to establish each
fuzzy set. They considered the impact of each assessment
item on disease degree based on specific literature, their
own daily experience in diagnosing these patients and the
simplicity of the screening method. For the MNSI ques-
tionnaire, items that assess nocturnal worsening of symp-
toms and past ulcers were weighted as 2.0 points, while
questions about numbness, burning, tingling, pins and the
diagnosis of neuropathy from another health professional
were weighted as 1.0 point. The physical evaluation of the
MNSI foot inspection scored 0.5 point, and the monofila-
ment and vibration perception tests scored 1.0 point each.
Each foot was evaluated separately.
The input variables were fuzzified using the following
linguistic terms:
(a) Symptom assessment (score): (1) absent, (2) low, (3)
moderate, or (4) high;
(b) Sign assessment (score): (1) absent, (2) low, (3) moder-
ate, or (4) high;
(c) HbA1c levels: (1) absent or (2) present;
(d) Diabetes duration (measured in years): (1) short, (2)
moderate, or (3) long.
The fuzzy output sets, shown in Figure 1, indicate the
degree of neuropathy. The sets were validated by expert
opinion using the following linguistic terms: absent neuro-
pathy, mild neuropathy, moderate neuropathy, and severe
neuropathy (Figure 2).
Based on the fuzzy input sets, linguistic rules were
elaborated using a combinatory analysis of those variables.
The consequence of each fuzzy rule was determined by the
experts, and 96 rules were elaborated in the form of the
following example:
‘‘IF symptom assessment is high AND sign assessment is
moderate AND HbA1c is present AND diabetes duration is
long THEN neuropathy is severe’’.
Using this set of rules and the system input and output
values, it is possible to assess the level of diabetic
neuropathy of any patient from which those input variables
were measured. Neuropathy severity was assessed by
means of a Mamdani inference process, and the Center of
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quantitative value for the neuropathy level, defined as a
number between 0 and 10.
We used a dataset comprising 50 hypothetical cases of
diabetic neuropathy elaborated by the experts to refine the
fuzzy model. To illustrate the mathematical function
determined by the rule base of the model, Figure 3 shows
the surface representing the severity of the disease based on
the inputted signs and symptoms.
Performance evaluation
We evaluated the model performance in two different
ways: i) we assessed the agreement between the model and
expert classifications with the Kappa test; and ii) we
evaluated the model sensitivity and specificity with an
ROC analysis, which is considered the gold standard for
neuropathy diagnosis.
For the agreement analysis, four experts evaluated a
separate set of 50 real cases based on clinical data gathered
Figure 1 - Linguistic terms used in the model input sets.
Figure 2 - Linguistic terms used in the model output sets.
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153from patient charts. Each case received a linguistic
classification indicating the degree of neuropathy (absent,
mild, moderate, or severe). The model produces numerical
values, which were sorted into the following classes: (i) 0 –
2.5: absent neuropathy; (ii) 2.6 – 4.5: mild neuropathy; (iii)
4.6 – 7.5: moderate neuropathy; and (iv) 7.6 – 10.0: severe
neuropathy.
The model results were compared with those provided
by each expert, and the expert analyses were compared
with each other. Thus, we were able to determine whether
model performance was consistent with human expert
assessments.
RESULTS
Table 1 shows the Kappa values for test agreement
between the model and the experts. The level of agreement
among experts was only moderate (23), highlighting the
uncertainty in classifying the degree of diabetic neuropathy
in these patients. The agreement between the model and the
experts was also moderate, i.e., the model agrees with the
experts as much as they agree with each other. In all
statistical tests, p,0.001.
Figure 4 shows the ROC performance of the model. The
area under the curve was 0.91, indicating that the model is
able to identify neuropathy in diabetic patients.
Figure 3 - Surface representing the severity of the disease based on symptoms and signs.
Table 1 - Kappa coefficient values between expert and
model ratings (p,0.001).
Expert 1 Expert 2 Expert 3 Expert 4
Expert 2 0.48 - - -
Expert 3 0.75 0.42 - -
Expert 4 0.44 0.22 0.51 -
Model 0.53 0.47 0.50 0.34
Figure 4 - ROC curve composed based on the gold standard
database.
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154DISCUSSION
There is no doubt that the process of identifying and
classifying diabetic patients as neuropathic is unclear and
subjective. Uncertainties in both symptom measurement
and diagnoses complicate this process. The skill and
experience of the expert evaluating the patient and the
available instruments are important factors. Thus, each
clinic sets its own protocols without an established
consensus.
Bus et al. (24) identified neuropathy based solely on the
10-g monofilament test or vibratory sensitivity. Allet et al.
(25) categorized neuropathy using only the vibratory
sensitivity test. However, the isolated use of different
identification and classification methods can lead to bias
because mild neuropathies often cannot be identified.
Moreover, symptoms may vary from patient to patient,
especially in the early stages of the disease. Although the
disease is symmetrical and distal, there can be differences in
the plantar areas affected by sensory impairments, the type
of foot deformity (cavus, planus, hammer toes, etc.) and the
extent of motor impairment. This means that one patient
may have clinical features that cannot be compared directly
to those of another patient, even if both patients were
diagnosed with the same degree of neuropathy.
Few studies have proposed the combination of several
techniques to identify diabetic neuropathy. For example,
Bacarin et al. (26) suggested the use of the MNSIq, 10-g
monofilament sensitivity test, and disease duration as
criteria for neuropathic severity. However, this proposal
does not take the vagueness of the diagnostic process into
account.
Few studies have sought to address these problems.
Duckstein et al. used fuzzy set structure to classify diabetic
neuropathy based on an invasive electrophysiological test
(27). However, this equipment requires specific knowledge
and appropriate professional training, and it is thus not
widely used in public health systems, especially in poorer
countries. Furthermore, although this test is very reliable, it
cannot detect neuropathy in the early stages of the disease.
Indeed, the electrophysiological test only provides clinically
useful information when neural degeneration has already
begun.
Conversely, the fuzzy model proposed here was based on
expert knowledge and four simple variables that are easily
determined in routine clinical assessments, avoiding the
necessity of sophisticated and invasive methods that require
a specially trained staff. The model was able to address
diagnostic and inter-measurement uncertainties, identify
neuropathy, and quantify its severity.
The agreement analysis presented here showed that this
model is able to classify the severity of the disease in the
same manner as human experts. This suggests that the
system would pass the Turing test. The moderate agreement
among the interviewed experts shows how difficult it is to
come to consensus on the clinical severity of neuropathy
based solely on physical anamnesis. Therefore, fuzzy theory
can be used to address this problem.
One of the most important contributions of this model is
its ability to detect diabetic neuropathy early in its
progression. The literature suggests that diabetic neuro-
pathy may be irreversible (2); therefore, timely preventive
intervention at early stages may help to ensure a better
quality of life for diabetic patients.
This paper proposes a fuzzy rule-based model to create
an expert system to support the classification of diabetic
neuropathy into different levels based on severity. The
model showed an adequate level of agreement with the
expert classifications, as well as high assessment accuracy in
real patients. The model is able to classify patients with
different degrees of neuropathy, which may improve
treatment effectiveness and aid health professionals in
managing this syndrome. This system supports the concept
of classifying patients with different degrees of diabetic
neuropathy, rather than identifying them as simply neuro-
pathic or non-neuropathic.
This model is able to match the ability of clinical experts
in classifying neuropathy severity in diabetic patients, and it
does not require sophisticated testing or equipment. This
model can be implemented in any public health system and
may serve as an important instrument for preventing
complications due to disease progression. The model also
enables immediate intervention in early stages of neuro-
pathy to maintain patient quality of life.
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